YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2022Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)ANNALS OF ONCOLOGY
2022Real-world prevalence of MSI-H/dMMR across 6 different tumor types in AsiaANNALS OF ONCOLOGY
2022Randomized phase II trial of upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy versus preoperative chemoradiotherapy followed by surgery and adjuvant chemotherapy in locally advanced rectal cancer: KCSG-CO14-10ANNALS OF ONCOLOGY
2022Real-world data on prevalence of MSI-H/dMMR across 6 solid tumor types in AsiaANNALS OF ONCOLOGY
2022Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertensionEXPERT OPINION ON DRUG SAFETY
2022Randomized phase II study of nalicap (nalIRI/capecitabine) compared to NAPOLI ( nal-IRI/5F-U/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progressJOURNAL OF CLINICAL ONCOLOGY
2022PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroupANNALS OF ONCOLOGY
2022PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03ANNALS OF ONCOLOGY
2022Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapyBLOOD
2022Prevalence and Risks of Depression and Substance Use Among Adults Living with HIV in the Asia-Pacific Region AIDS AND BEHAVIOR
2022Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancersANNALS OF ONCOLOGY
2022Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trialANNALS OF ONCOLOGY
2022Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011ANNALS OF ONCOLOGY
2022Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)ANNALS OF ONCOLOGY
2022Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerANNALS OF ONCOLOGY
2022Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progressJOURNAL OF CLINICAL ONCOLOGY
2022Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH)JOURNAL OF CLINICAL ONCOLOGY
2022Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancerANNALS OF ONCOLOGY
2022Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trialANNALS OF ONCOLOGY
2022Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trialJOURNAL OF CLINICAL ONCOLOGY
1 60 6162636465666768697071 691

Recent Submissions

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links